scholarly journals Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges

Kidney Cancer ◽  
2017 ◽  
Vol 1 (2) ◽  
pp. 107-114 ◽  
Author(s):  
Laure Fournier ◽  
Alexandre Bellucci ◽  
Yann Vano ◽  
Mehdi Bouaboula ◽  
Constance Thibault ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Current Status ◽  
Future Challenges ◽  
Immune Oncology ◽  
Imaging Response

Optimal Management of Metastatic Renal Cell Carcinoma: Current Status

Drugs ◽  
2013 ◽  
Vol 73 (5) ◽  
pp. 427-438 ◽  
Author(s):  
Bernard Escudier ◽  
Laurence Albiges ◽  
Guru Sonpavde
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Current Status ◽  
Optimal Management

scholarly journals Current status of prognostic factors in patients with metastatic renal cell carcinoma

2019 ◽  
Vol 26 (6) ◽  
pp. 608-617 ◽  
Author(s):  
Jun Teishima ◽  
Shogo Inoue ◽  
Tetsutaro Hayashi ◽  
Akio Matsubara
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factors ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Current Status

scholarly journals Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma

2012 ◽  
Vol 1 (2S) ◽  
Author(s):  
Anil K. Kapoor ◽  
Sébastien J. Hotte
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Current Status ◽  
Current Evidence ◽  
Cytokine Therapy ◽  
Current Standard ◽  
Significant Toxicity

Cytokine therapy with interferon-a and interleukin-2 has arguably been the standard treatment for patients with metastatic renal cell carcinoma for more than 20 years. In this paper, the current evidence for the use of cytokine therapy in this patient population is discussed, including the significant toxicity associated with these agents. A low overall response rate and a marginal survival advantage are observed with interferon-a and interleukin-2; however,these therapies have significant toxicity and impair quality of life. Unlike thecurrent tyrosine-kinase inhibitors, complete tumour responses may be seen with interleukin-2, but again this therapy has significant morbidity and mortality.Newer anti-angiogenesis agents may be combined with current standard cytokinetherapy for patients with metastatic renal cell carcinoma.

Current Status of Targeted Therapy in Metastatic Renal Cell Carcinoma

2007 ◽  
Vol 6 (10) ◽  
pp. 665-671 ◽  
Author(s):  
Pieter H.M. De Mulder ◽  
Jean-Jaques Patard ◽  
Cezary Szczylik ◽  
Thomas Otto ◽  
Tim Eisen
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Current Status

Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives

2013 ◽  
Vol 13 (6) ◽  
pp. 697-709 ◽  
Author(s):  
Matteo Santoni ◽  
Michele De Tursi ◽  
Alessandra Felici ◽  
Giovanni Lo Re ◽  
Riccardo Ricotta ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Current Status ◽  
Future Perspectives ◽  
Poor Risk

scholarly journals The current status of immunobased therapies for metastatic renal-cell carcinoma

2017 ◽  
Vol Volume 6 ◽  
pp. 83-93 ◽  
Author(s):  
Niranjan J Sathianathen ◽  
Suprita Krishna ◽  
J Kyle Anderson ◽  
Christopher J Weight ◽  
Shilpa Gupta ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Current Status
Sign in / Sign up

Export Citation Format

Share Document